Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nuclear sclerosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Nuclear sclerosis. Displaying page 1 of 1.
    EudraCT Number: 2010-023172-12 Sponsor Protocol Number: EFC6058 Start Date*: 2011-02-15
    Sponsor Name:sanofi-aventis recherche et development
    Full Title: A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) HU (Completed) BE (Prematurely Ended) SE (Completed) EE (Completed) GB (Prematurely Ended) SK (Completed) ES (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GR (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002654-95 Sponsor Protocol Number: NET-MS Start Date*: 2023-04-17
    Sponsor Name:FONDAZIONE ITALIANA SCLEROSI MULTIPLA ONLUS
    Full Title: No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000395-26 Sponsor Protocol Number: GER-BGT-13-10586 Start Date*: 2015-08-07
    Sponsor Name:Biogen GmbH
    Full Title: A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001484-27 Sponsor Protocol Number: NL67672.091.18 Start Date*: 2023-01-24
    Sponsor Name:radboudumc
    Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2
    Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004328-40 Sponsor Protocol Number: INMINDFP7-HEALTH-2011-two-stage Start Date*: 2013-03-01
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES
    Medical condition: mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002318-11 Sponsor Protocol Number: 109MS306 Start Date*: 2014-06-05
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) IT (Completed) HU (Completed) DK (Completed) CZ (Completed) PL (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) DE (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005418-31 Sponsor Protocol Number: COMB157G2301 Start Date*: 2016-10-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) HU (Completed) GB (Completed) SE (Completed) DK (Completed) CZ (Completed) SK (Completed) ES (Completed) NL (Completed) EE (Completed) BG (Completed) GR (Completed) PL (Completed) HR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002628-34 Sponsor Protocol Number: thorp8617-1 Start Date*: 2012-08-29
    Sponsor Name:Thor Petersen
    Full Title: Optic neuritis and early treatment with methylprednisolone.
    Medical condition: Optic neuritis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10030946 Optic neuritis, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002855-25 Sponsor Protocol Number: EIP-VX00-745-302 Start Date*: 2015-03-11
    Sponsor Name:EIP Pharma, LLC
    Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ...
    Medical condition: Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002066-39 Sponsor Protocol Number: REPEXStudy Start Date*: 2013-09-04
    Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale "S.Maria Nuova"/IRCCS
    Full Title: The Reggio Emilia study on bromfenac for patients with PseudoEXfoliation syndrome undergoing cataract surgery: the REPEX study
    Medical condition: Postoperative inflammation in patients with pseudoexfoliatio lentis undergoing cataract surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003705-42 Sponsor Protocol Number: 15-09 Start Date*: 2016-02-18
    Sponsor Name:VU University Medical Center
    Full Title: Longitudinal imaging of tau accumulation in the preclinical stages of AD
    Medical condition: Alzheimer's Disease (AD), preclincal stages of AD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004230-10 Sponsor Protocol Number: 15-14 Start Date*: 2016-11-16
    Sponsor Name:VU University Medical Center
    Full Title: Validating in vivo quantification of tau with [18F]AV-1451 PET
    Medical condition: Alzheimer's Disease (AD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    18.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    18.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-005830-14 Sponsor Protocol Number: CVAY736K12301 Start Date*: 2022-07-04
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patien...
    Medical condition: Lupus nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) EE (Trial now transitioned) LT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-004090-29 Sponsor Protocol Number: AVD100521 Start Date*: 2005-02-07
    Sponsor Name:GlaxoSmithKline Research & Development Ltd [...]
    1. GlaxoSmithKline Research & Development Ltd
    2. GlaxoSmithKline R&D
    Full Title: A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type ...
    Medical condition: atherosclerosis in Type 2 Diabetes Mellitus patients with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003601 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) LV (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004136-36 Sponsor Protocol Number: 1002-040 Start Date*: 2016-06-14
    Sponsor Name:Esperion Therapeutics, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY C...
    Medical condition: Treatment of high cardiovascular risk patients (heterozygous familial hypercholesterolemia [HeFH] and atherosclerotic cardiovascular diseases [ASCVD]) with hyperlipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000019513 10020604 Hypercholesterolemia LLT
    20.0 100000019521 10020667 Hyperlipidemia LLT
    20.0 100000022953 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000012386 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:20:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA